Trial Information
Inclusion Criteria:
- Male or female, age 21 to 70 years old.
- Patient undergoing with anti-neoplastic agent(s) known to have genotoxic activity
(e.g., cyclophosphamide, 5-FU, cisplatin, Ara-C.
- X-irradiation may be considered, so long as a substantial fraction of red marrow is
exposed (e.g., femur or chest/trunk region);
- treatment could be ongoing therapy or initial therapy.
Type of Study:
Observational
Study Design:
Observational Model: Defined Population, Time Perspective: Longitudinal, Time Perspective: Prospective
Principal Investigator
Yuhchyau Chen, MD, Ph.D
Investigator Role:
Principal Investigator
Investigator Affiliation:
Universtiy of Rochester, Dept of Radiation Oncology
Authority:
United States: Institutional Review Board
Study ID:
URCC 1702
NCT ID:
NCT00178308
Start Date:
Completion Date:
Related Keywords:
Name | Location |
University of Rochester |
Rochester, New York 14642 |